慢性肺实质疾病相关肺动脉高压:新疗法的未来展望
综述探讨慢性肺实质疾病相关肺动脉高压的治疗现状与未来方向。现有指南推荐优化基础肺病治疗包括长期氧疗,但缺乏随机对照试验支持。已获批的肺动脉高压药物在间质性肺疾病和慢阻肺相关肺动脉高压的随机对照试验结果令人失望,部分试验因治疗组死亡和主要不良事件增加而提前终止。未来需选择稳健终点和特定血流动力学标准的目标人群以评估创新治疗策略。
要点
- 慢性肺病相关肺动脉高压预后差,指南推荐优化基础肺病治疗包括长期氧疗但缺乏随机对照试验支持。
- 已获批的肺动脉高压药物在间质性肺疾病和慢阻肺相关肺动脉高压的随机对照试验结果令人失望。
- 部分试验因治疗组死亡和主要不良事件增加而提前终止,未来需选择稳健终点和特定血流动力学目标人群。
核心结论
- 慢性肺实质疾病相关肺动脉高压预后差,现有肺动脉高压药物随机对照试验结果令人失望,部分因治疗组死亡和主要不良事件增加而提前终止。
研究设计与样本
- 综述,讨论慢性主要呼吸疾病相关肺动脉高压的近期研究和临床试验及未来治疗策略评估场景。
主要发现
- 已获批的肺动脉高压药物在间质性肺疾病和慢阻肺相关肺动脉高压的随机对照试验结果令人失望。
- 部分试验因治疗组死亡和其他主要不良事件增加而提前终止。
- 特发性肺纤维化相关肺动脉高压的新疗法研究采用新型抗纤维化治疗与肺动脉高压获批药物联合。
关键数值与推荐
- 更新版肺动脉高压指南推荐优化基础肺病治疗包括长期氧疗用于慢性低氧血症患者,但缺乏随机对照临床试验支持。
临床怎么用
- 临床应优化基础肺病治疗包括长期氧疗,对慢性肺病相关肺动脉高压使用肺动脉高压药物需谨慎。
- 未来治疗策略评估需选择稳健终点和特定血流动力学标准的目标人群。
局限性
- 缺乏随机对照临床试验支持指南推荐。
- 已获批肺动脉高压药物在间质性肺疾病和慢阻肺相关肺动脉高压的随机对照试验结果令人失望。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary hypertension (PH) due to chronic lung disease is associated with a poor prognosis, regardless of the underlying respiratory condition. Updated PH guidelines recommend optimal treatment of the underlying lung disease, including long-term oxygen therapy, in patients with chronic hypoxemia despite the lack of randomized controlled clinical trials supporting this statement. So far, randomized controlled trials of drugs approved for pulmonary arterial hypertension have yielded discouraging results in both interstitial lung diseases and COPD with PH. In some cases, the trials were terminated because of an increase in death and other major adverse events in the active treatment arm vs placebo. In cases of PH due to idiopathic pulmonary fibrosis, new therapies under investigation use a combination of novel antifibrotic treatments and other treatments approved for pulmonary arterial hypertension. The choice of robust end points as well as a target group of patients with specific hemodynamic criteria may help in the selection of innovative therapeutic strategies. The aim of this review is to discuss recent studies and clinical trials for the treatment of PH due to the main chronic respiratory diseases and to discuss possible future scenarios for the evaluation of new therapeutic strategies.
引用
- Harari S, Elia D, Humbert M, et al. Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies? Chest. 2017. PMID: 28629920. doi:10.1016/j.chest.2017.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。